

Notice to 340B Covered Entities

Zestril® Limited Distribution – Effective July 15, 2020

NDC	PRODUCT
52427-0438-90	Zestril Tablets 2.5mg
52427-0439-90	Zestril Tablets 5mg
52427-0440-90	Zestril Tablets 10mg
52427-0441-90	Zestril Tablets 20mg
52427-0442-90	Zestril Tablets 30mg
52427-0443-90	Zestril Tablets 40mg

Almatica Pharma, LLC (“Almatica”) distributes Zestril® (lisinopril), which is indicated for the treatment of hypertension. During 2Q2020, we experienced a shortage due to demand and we anticipate product shortage through the 3Q2020. In an effort to ensure that all of our customers (including 340B covered entities) have an equal opportunity to obtain Zestril®, we are instituting a limited distribution system for this product, effective **July 15, 2020**. The limited distribution system will affect all customers in a fair and consistent fashion, allowing 340B covered entities to purchase at the published 340B price. We anticipate that this system will remain in place for the foreseeable future.

In light of this shortage, Almatica will limit each customer’s monthly purchases of Zestril® to twice its historical average monthly ordering volume during 4Q2019 and 1Q2020. We have advised our wholesalers of their purchasing limits and have asked them to limit Zestril® resales to their downstream customers, applying this same methodology on a customer-by-customer basis. Once a customer reaches its limit for a given month, it may place additional order for Zestril® at the beginning of the next month, up to that next month’s limit. For a customer with no purchases of Zestril® in 4Q2019 or 1Q2020, Almatica will establish a monthly maximum order quantity based on the overall average monthly purchase volume of customers in that new purchaser’s class of trade. We will apply this average equally to all such customers, importantly, a customer’s 340B covered entity status will not affect its monthly allocation which is based solely on historical unit purchasing volumes.

Almatica is committed to making Zestril® equitably available to all U.S. customers, including 340B covered entities, through the limited distribution system described in this notice. If you have any questions regarding this notice, please feel free to contact Almatica Customer Service at 844-889-8686, Option #1 or Almatica-CustomerService@Alvogen.com.

Respectfully,

Almatica Pharma